Navigation Links
Study Demonstrates Pine Bark Naturally Improves Tinnitus
Date:10/13/2010

HOBOKEN, N.J., Oct. 13 /PRNewswire/ -- More than 50 million Americans will experience some degree of tinnitus in their lifetime, according to the American Tinnitus Association.  Tinnitus is a hearing condition that causes the constant misperception of sound, including hissing, ringing and rushing noises.  A study recently published in Panminerva Medica reveals that Pycnogenol® (pic-noj-en-all), an antioxidant plant extract derived from the bark of the French maritime pine tree, is effective in relieving tinnitus symptoms by improving blood flow in the inner ear.

"Impaired blood flow to the ear is a common cause for tinnitus, a disturbing and very debilitating condition that can considerably impact overall health and quality of life," said Dr. Gianni Belcaro, a lead researcher on the study along with his team from Irvine3 Vascular labs, Chieti-Pescara University.  "With few options available for treatment, this study gave us the opportunity to explore a natural solution to tinnitus symptoms and its causes."

In a study conducted by the Chieti-Pescara University in Italy, 82 patients between the ages of 35 and 55 with mild-to-moderate tinnitus in only one ear, while the other remains unaffected, were studied throughout a four-week period.  Tinnitus in all subjects was a result of restricted blood supply to the inner ear, as measured by high resolution ultrasonography imaging of their cochlear blood flow.  Patients were assigned to one of three groups: A, B and control.  Group A consisted of 24 patients who were administered 150 mg/day of Pycnogenol®, group B consisted of 34 patients who were administered 100 mg/day of Pycnogenol®, and the control group consisted of 24 patients who received no Pycnogenol®.  None of the patients had previously used medication for their tinnitus symptoms.  

At the beginning of the study, patients' average initial systolic and diastolic blood flow velocities were 14.3 and 4.22 cm/sec in the low dose Pycnogenol® group and 13.2 and 3.2 cm/sec in the high dose Pycnogenol® group, indicative of insufficient blood perfusion of the ear in both groups.  The study found that after four weeks of treatment with Pycnogenol®, inner ear systolic and diastolic blood flow velocities in the affected ear rose to an average of 21.2 and 8.23 cm/sec in the low dose group and to 24.3 and 12.5 cm/sec in the high dose group.  Not only are these results significant for the improvement of inner ear blood micro-circulation and, consequently reduction of tinnitus symptoms, but they also indicate the potentially dose-related effect of Pycnogenol® on the condition.

The study also examined in detail the effects of Pycnogenol® on the symptoms of tinnitus.  Using a Subjective Tinnitus Scale (STS) at the inception of the study, subjects were instructed to rate their symptoms from "zero" (low intensity of symptoms) to "fifteen" (constant and severe symptoms).  The initial STS average value was approximately 8.8 among patients in the Pycnogenol® group and 7.9 in the control group.  After four weeks, STS scores reduced to 5.2 in the low dose group and 3.3 in the high dose group, demonstrating a dramatic reduction of the disturbing background noise in the effected ear.  There were no significant changes within the control group.

"The study clearly indicates Pycnogenol®'s ability to improve vascular function and restore cochlear blood perfusion, which in turn relieves the severity of tinnitus symptoms" said Dr. Belcaro.  "The results provide further evidence of the supplement's natural efficacy for a variety of vascular health symptoms."

This study further corroborates Pycnogenol®'s prominence for improvement of vascular function which spans from the large arteries and veins to the tiniest micro-vessels.

Pycnogenol® is a proprietary, patented pine bark extract and the research findings detailed here and in other published journals may not be applied to other pine bark extracts on the market.

About Pycnogenol®

Pycnogenol® is a natural plant extract originating from the bark of the maritime pine that grows along the coast of southwest France and is found to contain a unique combination of procyanidins, bioflavonoids and organic acids, which offer extensive natural health benefits.  The extract has been widely studied for the past 40 years and has more than 230 published studies and review articles ensuring safety and efficacy as an ingredient.  Today, Pycnogenol® is available in more than 700 dietary supplements, multi-vitamins and health products worldwide.  For more information, visit www.Pycnogenol.com.

About Natural Health Science, Inc.

Natural Health Science Inc. (NHS), based in Hoboken, New Jersey, is the North American distributor for Pycnogenol® (pic-noj-en-all) brand French maritime pine bark extract on behalf of Horphag Research.  Pycnogenol® is a registered trademark of Horphag Research Ltd., Guernsey, and its applications are protected by U.S. patents #5,720,956 / #6,372,266 and other international patents.  Horphag Research Ltd. Is the recipient of the 2008 Frost & Sullivan North American Health Ingredients Excellence in Research Award.  NHS has the exclusive rights to market and sell Pycnogenol® in North America and benefits from more than 40 years of scientific research assuring the safety and efficacy of Pycnogenol® as a dietary supplement.  For more information about Pycnogenol® visit our Web site at www.Pycnogenol.com.


'/>"/>
SOURCE Natural Health Science, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardiogenesis Enrolls First Two Patients in Its Feasibility Study of the PHOENIX® Combination Delivery System
2. Results of Innovative Clinical Study Show New Combination for Weight Loss Success
3. Archimedes Pharma Announces Publication of Long-Term Safety and Tolerability Clinical Study of Fentanyl Pectin Nasal Spray (FPNS) in the Journal of Opioid Management
4. Ocular Therapeutix Completes Proof of Principle Study with Moxifloxacin-Loaded Punctum Plugs
5. BiondVax Begins Phase IIa Study for Universal Flu Vaccine
6. New Soy-Based Natural S-equol Supplement Reduces Menopausal Hot Flashes, Muscle and Joint Pain in First Study Among U.S. Women
7. New Study Published in Journal of Drugs in Dermatology Finds Artefill Effective in Treating Atrophic Acne Scars
8. U-M Receives NIH, FDA Grant To Study Adaptive Clinical Trial Design
9. Study Demonstrates Safety and Efficacy of Subcutaneous Vivaglobin® as First-Line Therapy for Primary Immunodeficiency
10. Obstetrics and Gynecology Publishes Data From Pivotal Phase 3 LYSTEDA Study
11. ISTA Pharmaceuticals Reports Positive Preliminary Results from its Phase 1/2 Clinical Study of Bepotastine Besilate Nasal Spray for the Treatment of Symptoms Associated with Seasonal Allergic Rhinitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... N.C. , Feb. 8, 2016  Avista Pharma ... Eric Setzer as Chief Financial Officer (CFO). Mr. ... twenty years of experience in various roles within growing ... Pharma, he served as the Executive Director of Finance ... in Raleigh, NC . Previously, Mr. ...
(Date:2/8/2016)... , Feb. 8, 2016 Velano Vascular, ... experience for hospitalized patients and their practitioners, announced today ... in funding. Velano will use the proceeds from this ... financing completed in January 2015, to support the development ... adult and pediatric populations. Philadelphia ...
(Date:2/8/2016)... -- Vestagen Technical Textiles, Inc., a medical technology company ... other demanding applications, today announced it has named ... Dale Pfost , PhD, who was serving as interim ... Vestagen,s Board of Directors. ® , the ... that combines fluid repellent, antimicrobial and breathability properties. VESTEX ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... ... redesigned website, federallabs.org . The site houses a wealth of federal resources ... technologies through the process called technology transfer (T2). As a network of over ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... Houma, LA, celebrates the beginning of a new charity campaign. As part of ... Appointed Special Advocates (CASA). In the belief that children deserve a voice, and ...
(Date:2/8/2016)... ... February 08, 2016 , ... Brenton Engineering , ... bags, and flow wrapped products at WestPack 2015, February 9-11, in Anaheim, California. ... up to semi-automatic or fully-automatic case packing with a small footprint, rugged, highly ...
(Date:2/8/2016)... Island, SC (PRWEB) , ... February 08, 2016 , ... ... surrounding areas with a vital new community enrichment program, has teamed up with Citizens ... women and children suffering from intimate abuse. To support all those victimized by the ...
(Date:2/8/2016)... CA (PRWEB) , ... February 08, 2016 , ... Delta ... $792,000 to help combat pancreatic cancer. , Gary D. Radine, who recently retired as ... was the American Cancer Society’s 2015 CEO of the Year , helped lead ...
Breaking Medicine News(10 mins):